AllianceBernstein Holding L.P.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Seth Perry Bernstein
- Full Time Employees
- 4,468
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 501 Commerce Street Nashville TN United States of America 37203
- IPO Date
- Apr 14, 1988
- CIK
- 0000825313
- Website
- alliancebernstein.com
- Similar Companies
- Business
- AllianceBernstein Holding L.P. (AB) is a global investment management firm that provides diversified research, portfolio management, and related services to institutional investors, high-net-worth individuals, financial advisors, and retail clients worldwide. The company offers a comprehensive range of investment products and services, including equities; fixed income, encompassing tax-exempt and corporate securities; multi-asset solutions; alternatives and private markets; retirement and defined contribution products such as 401(k) plans; and wealth management offerings for private clients. It primarily invests in common and preferred stocks, warrants, convertible securities, government and corporate fixed-income securities, commodities, currencies, real estate-related assets, and inflation-protected securities, employing quantitative analysis, long-term and short-term purchases, trading, short sales, margin transactions, and option strategies including covered and uncovered options. Founded in 1967 through the establishment of Sanford C. Bernstein & Co. and subsequent merger activities leading to its current form in 2000, AllianceBernstein Holding L.P. is headquartered in Nashville, Tennessee, with additional offices in New York and operations across global markets including the United States, Europe, and Asia. The firm serves a broad client base comprising U.S. public and private employee benefit plans, foundations, endowments, pension funds, sovereign wealth funds, insurance companies, banks, and investment companies. In recent developments, Equitable Holdings, Inc., which holds a significant economic interest in AllianceBernstein, announced a cash tender offer in February 2025 to purchase up to 46 million units of AB Holding at a premium, aiming to increase its ownership in the operating partnership to approximately 77.5%. The company reported strong third-quarter 2025 results, including $1.7 billion in net inflows excluding a specific reinsurance transaction, with $4.1 billion into its tax-exempt fixed income franchise and $3.2 billion into private alternatives, advancing private markets assets under management toward a $90-100 billion target by 2027. AllianceBernstein also announced a strategic partnership focused on the Asian insurance market, expanded its lifetime income platform with a fixed annuity version of the Secure Income Portfolio, and earned the Money Management Institute/Barron's 2025 Industry Award for Asset Manager of the Year in the retail advisory category.
AB Announces June 30, 2026 Assets Under Management
AB to Report Second Quarter 2026 Results on July 28, 2026
AllianceBernstein Global High Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
AllianceBernstein National Municipal Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
Forget Big Tech: Nancy Pelosi Just Poured Millions Into This Under-the-Radar Dividend Stock
AB Akola Group notification on transactions in the Company's securities by the person discharging managerial responsibilities
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
AB Announces May 31, 2026 Assets Under Management
New Strong Sell Stocks for May 28th
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
AB Science annonce que le titre AB Science continue d’être couvert par Maxim Group, avec un objectif de cours de 4,00 € par action
AllianceBernstein Global High Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
AllianceBernstein National Municipal Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
New Strong Sell Stocks for May 21st
AllianceBernstein, Brookfield, and Carlyle Unveil Turnkey Private-Markets Solution for Defined Contribution Plans
New Strong Sell Stocks for May 19th
AB Science reports its revenues for the year 2025 and provides an update on its activities
AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2025 et présente un point sur ses activités